Filing Details
- Accession Number:
- 0001209191-23-041393
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-07-05 21:08:45
- Reporting Period:
- 2023-07-03
- Accepted Time:
- 2023-07-05 21:08:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1496323 | Igm Biosciences Inc. | IGMS | Pharmaceutical Preparations (2834) | 770349194 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1857434 | George Gauthier | C/O Igm Biosciences, Inc. 325 E. Middlefield Road Mountain View CA 94043 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-07-03 | 936 | $9.42 | 40,017 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- The sale reported by the Reporting Person was effected pursuant to a Rule 10b5-1 trading plan, entered into on December 29, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
- This transaction was executed in multiple trades at prices ranging from $9.22 to $9.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Billionaire Hedge Funds
